Androgenetic Alopecia: What It Is, What Causes It, and What the Options Are
Published by AmpleLab Research
Androgenetic alopecia is the most prevalent form of hair loss in adults. It affects an estimated 50% of men by the age of 50 and a significant proportion of women across all age groups, with prevalence rising sharply after menopause. It follows recognisable patterns, progresses gradually over years, and is driven by a combination of genetic susceptibility and hormonal signalling. Despite how common it is, it is frequently misunderstood: the role of androgens is real but not universal, the genetics are more nuanced than the popular assumption that baldness comes from the maternal side, and the treatment landscape extends well beyond the two medications most people encounter first.
This article brings together the biology, classification, and treatment options for AGA in one place, and links to dedicated companion articles where individual topics are covered in depth.
What Is Androgenetic Alopecia?
Androgenetic alopecia is a non-scarring, progressive condition in which genetically susceptible hair follicles respond to androgen signalling by gradually producing finer, shorter, and less pigmented hair over successive growth cycles, a process called miniaturisation. The follicles are not destroyed, at least not in early and intermediate stages: they remain but become progressively less functional. This distinction matters clinically, because a miniaturised follicle may still be capable of producing terminal hair if the conditions driving miniaturisation are addressed before the follicle undergoes permanent structural change.
The term "androgenetic" points to both of its primary contributors: androgen sensitivity in the follicle, and the genetic predisposition that determines which follicles carry that sensitivity and how strongly it is expressed. Neither alone is sufficient. Men born with a complete absence of functional androgen receptors do not develop AGA regardless of their genetic background. And not everyone with the relevant genetic variants will develop significant hair loss; penetrance and expressivity vary considerably between individuals.
Prevalence estimates vary depending on methodology and the thresholds used to define "affected," but the pattern is consistent: AGA affects roughly 16% of men in their twenties, rising to approximately 53% by the fifth decade and around 80% by the eighth. In women, the overall prevalence is lower and the relationship with age differs, with a marked increase around and after menopause. The presentation in women, often called female pattern hair loss (FPHL), involves a different spatial pattern and a more complex hormonal picture; it is covered in the dedicated article on female pattern hair loss.
The Genetic Component
AGA is polygenic: it results from the combined effect of many genetic variants rather than a single gene. The most strongly associated factor is a variant in the androgen receptor (AR) gene on the X chromosome. Because men inherit their X chromosome from their mothers, maternal-line baldness is a stronger predictor of risk than paternal-line baldness, and this has given rise to the common belief that baldness comes from the mother's side. The reality is more complicated. Genome-wide association studies have identified dozens of additional risk loci on autosomal chromosomes, meaning variants from either parent contribute meaningfully to overall risk. A man can carry significant AGA susceptibility through his father's family even if his mother's family shows no pattern of hair loss.
What these variants collectively determine is how sensitive follicular androgen receptors are to DHT signalling, how much 5-alpha reductase activity is expressed locally in dermal papilla cells, and which scalp regions carry the highest receptor density. These variables govern both whether AGA develops and how severe it becomes across an individual's lifetime.
The Androgen Pathway
The primary hormonal driver of AGA in men is dihydrotestosterone (DHT). Testosterone is converted to DHT within follicle dermal papilla cells, principally by the type II isoform of 5-alpha reductase. DHT binds androgen receptors with higher affinity and a slower dissociation rate than testosterone, making it a more potent activator of androgen-responsive gene expression despite being present at lower concentrations in the bloodstream.
When the DHT-receptor complex translocates to the nucleus of dermal papilla cells, it alters the gene expression profile in ways that progressively curtail anagen and reduce follicle size. The downstream result is miniaturisation: across successive hair cycles, the follicle produces progressively shorter, finer, and less pigmented hair. Research has confirmed that dermal papilla cells from balding scalp regions express androgen receptors at substantially higher levels than cells from non-balding regions in the same individual, which explains the regional specificity of the condition. It is not a difference in circulating hormone levels that determines which follicles are affected; it is a difference in how those follicles respond to the same hormonal environment.
The molecular detail of this pathway, including the specific downstream signalling mediators and the distinction between type I and type II 5-alpha reductase, is covered in the article on DHT and the follicle.
The Miniaturisation Cascade: How AGA Progresses Cycle by Cycle
Hair grows in cycles. Each cycle consists of an active growth phase (anagen), a short transitional phase (catagen), and a resting phase (telogen), after which the follicle re-enters anagen and begins producing a new shaft. In a healthy terminal follicle, anagen typically lasts two to six years. In a follicle undergoing AGA-related miniaturisation, DHT signalling progressively shortens anagen with each successive cycle while telogen remains relatively unchanged. The follicle produces a slightly finer and shorter shaft with each cycle, and the proportion of miniaturised follicles in any given scalp region increases gradually over time.
This is why AGA develops slowly over years rather than abruptly, and why early intervention is clinically meaningful: a follicle producing finer hair with a shortened anagen is considerably more responsive to treatment than one that has been miniaturising for a decade. The hair growth cycle and how androgenic signalling disrupts it are covered in more detail in the article on the hair growth cycle.
Terminal hair: Long anagen (2 to 6 years), deep follicle anchor, thick pigmented shaft. The hair produced by a healthy, unsuppressed scalp follicle.
Miniaturised intermediate hair: Shortened anagen (months rather than years), reduced shaft diameter, partial depigmentation. Clinically visible as thinning and reduced density before overt baldness.
Vellus hair: Very short anagen, superficial follicle, barely visible unpigmented shaft. The endpoint of the miniaturisation process in severely and chronically affected follicles.
Beyond Androgens: Vascular Changes and Perifollicular Fibrosis
The androgen pathway is the primary and best-characterised mechanism in AGA, but it does not account for the full picture. Research has also identified structural changes in the scalp microenvironment of affected regions: specifically, progressive perifollicular fibrosis and a reduction in the density and activity of the capillary network supplying individual follicles. These observations have led to what is often called the vascular hypothesis for AGA.
Follicles require a rich blood supply during anagen to sustain the metabolic demands of rapid cell proliferation. Research suggests that vascular endothelial growth factor (VEGF) expression in the dermal papilla is tightly coupled to the hair cycle, rising during anagen and falling at catagen, and that the capillary network around the follicle expands and contracts in parallel. If vascular support is insufficient, the follicle may be unable to sustain productive anagen regardless of its androgen receptor status. Separately, perifollicular fibrosis, the deposition of collagen around miniaturising follicles, has been observed in balding regions to a degree not seen in non-balding regions of the same scalp. Researchers have proposed that this fibrosis may form a physical and biochemical barrier that further restricts follicle function as the condition progresses.
On the Evidence
The vascular and fibrotic components of AGA are supported by consistent mechanistic and correlational evidence. They have not been tested as independent therapeutic targets in large randomised controlled trials. The vascular hypothesis is a well-evidenced framework rather than a proven causal model.
These are not competing explanations for AGA; they are additional layers of the same disease environment. The vascular hypothesis has practical implications for how treatment protocols are constructed, because it expands the target space beyond androgen suppression alone. The evidence is covered in detail in the article on androgenetic alopecia and the vascular hypothesis.
Recognising AGA: Pattern and Classification
In men, AGA is classified using the Norwood scale, which describes seven stages from no significant recession through to near-complete loss across the top of the scalp with only a narrow horseshoe-shaped band remaining at the sides and back. The intermediate stages capture the characteristic progression: temporal recession and vertex thinning developing independently before eventually merging across the crown. The scale also includes "A" variants for men whose recession advances from front to back as a single front without forming the distinct vertex island that characterises the standard stages.
Women with AGA typically present with diffuse crown and midscalp thinning with preservation of the frontal hairline, classified using the Ludwig scale (Stages I through III). The spatial pattern, the hormonal drivers, and the appropriate treatment approach differ substantially from the male presentation. These differences are covered in the article on female pattern hair loss.
AGA can sometimes be difficult to distinguish from telogen effluvium (TE), which causes diffuse shedding rather than patterned loss, and the two conditions can co-occur. The article on telogen effluvium vs androgenetic alopecia covers how to distinguish between them.
Treatment Options: What the Evidence Shows
No treatment reverses advanced AGA. What the available interventions can do, in varying degrees, is slow or halt progression, partially reverse miniaturisation in follicles that retain the capacity to respond, and support the scalp microenvironment in ways that may improve outcomes over time. The options span pharmaceutical treatments, topical actives, and procedural approaches, and they address different mechanisms.
5-alpha reductase inhibitors represent the most direct pharmacological approach to AGA. Finasteride (1mg daily) inhibits the type II isoform of 5-AR; dutasteride (0.5mg daily) inhibits both type I and type II, producing more complete DHT suppression. Clinical trials have consistently demonstrated that finasteride halts progression in the majority of male users and produces measurable regrowth in a significant proportion over 12 to 24 months. Dutasteride appears more effective in some comparative studies, though its hormonal impact is correspondingly more extensive.
Both are prescription medications in the UK. Both carry a documented risk of sexual side effects in a minority of users; persistent sexual dysfunction following discontinuation has been reported in a subset of people. Finasteride is not licensed for use in women of childbearing potential. Topical finasteride, applied directly to the scalp, is increasingly available and may offer lower systemic exposure, though the evidence base is less mature than for oral use; the same route exists for topical dutasteride, with a thinner evidence base still. A full comparison of the two drugs is covered in finasteride vs dutasteride: a direct comparison. These are decisions that require clinical assessment.
Minoxidil's best-characterised molecular action is opening ATP-sensitive potassium channels, with downstream effects that include VEGF upregulation, anagen prolongation, and increased follicle size. Unlike 5-AR inhibitors, it does not address the androgen pathway directly. It is available without prescription as a topical solution or foam (2% and 5%), and oral low-dose minoxidil (0.25 to 2mg daily) has gained considerable clinical traction in recent years, with good evidence for both male and female presentations.
An initial shedding phase in the first four to eight weeks of topical minoxidil use is common and typically reflects telogen follicles being pushed into anagen rather than worsening of the underlying condition. Discontinuation results in reversion to the pre-treatment state within several months, which has important implications for long-term planning. Oral minoxidil delivers the active regardless of application technique, but carries cardiovascular considerations that make it a clinical decision for most people rather than a self-managed one. A full breakdown of the mechanism, formulations, and evidence is covered in minoxidil for hair loss.
Topical actives do not address the androgen pathway directly. Their rationale is the broader scalp microenvironment: supporting vascularity, modulating fibrotic signalling, and providing the follicle with biochemical cues associated with healthy-cycle activity. They are complementary to androgen-targeted treatments rather than substitutes for them. The evidence base varies by compound.
Among copper peptides, AHK-Cu (Copper Tripeptide-3) has some of the most direct hair-specific research. Research suggests it upregulates VEGF in dermal papilla cells and promotes anagen-phase activity. The 1% AHK-Cu Hair and Scalp Serum delivers the active at the concentration used in published research.
GHK-Cu (Copper Tripeptide-1) is more broadly studied for tissue remodelling, collagen synthesis, and anti-fibrotic activity. In the context of AGA, its potential to modulate TGF-beta-mediated fibrosis is the most mechanistically relevant property, given the perifollicular fibrosis observed in balding scalp regions. The 1% GHK-Cu Face and Skin Serum is used by some in scalp protocols for this reason, though the primary research base for GHK-Cu is in skin biology rather than hair growth specifically.
2-Deoxy-D-Ribose (2dDR) is an angiogenic compound with a distinct mechanism: it promotes new capillary formation and upregulates VEGF in endothelial cells. At 2% concentration in an animal hair model, it has been shown to increase follicle size and hair shaft length. The 2% 2dDR Hair Serum targets the vascular dimension of the scalp microenvironment rather than androgen signalling.
Scalp microneedling creates controlled micro-injury that triggers a localised wound-healing response, including VEGF and PDGF release and increased perifollicular blood flow. Small clinical studies have found that microneedling used alongside minoxidil produced better outcomes than minoxidil alone in some patient groups. It also enhances the penetration of topical actives applied immediately after. The practical guidance for combining microneedling with topical compounds is covered in the article on microneedling and topical actives.
Hair transplantation (principally FUE and FUT techniques) relocates DHT-resistant occipital follicles to areas of thinning or loss. Because the transplanted follicles carry the androgen resistance of their original location, they continue to produce terminal hair in the recipient site. Transplantation addresses the cosmetic result of hair loss rather than the underlying process: without ongoing medical treatment in non-transplanted regions, AGA may continue to progress around transplanted hair. It is typically most appropriate for individuals with stabilised loss and sufficient donor density, assessed at Norwood Stage III to V in most clinical contexts.
Building a Protocol
The available treatments for AGA address different aspects of the condition. DHT suppression targets the primary androgen pathway. Minoxidil targets vascular activity and anagen maintenance. Topical actives and microneedling target the scalp microenvironment. These are not competing approaches: they are mechanistically distinct and largely complementary, and the clinical evidence generally supports layering treatments that address different pathways rather than relying on any single intervention.
A practical framework for deciding which interventions to combine, in what sequence, and at what frequency is covered in the article on how to build a hair loss protocol. For those combining copper peptides with minoxidil, specific evidence and compatibility guidance is in can you use copper peptides and minoxidil together. Realistic timelines for topical interventions are covered in how long before you see results from a hair loss serum.
Selected Research
Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp
Hibberts NA, Howell AE, Randall VA — Journal of Endocrinology, 1998 PubMed ↗
Androgens and hair growth
Randall VA — Dermatologic Therapy, 2008 PubMed ↗
Perifollicular fibrosis: pathogenetic role in androgenetic alopecia
Yoo HG, Kim JS, Lee SR, Pyo HK, Moon HI, Lee JH, Kwon OS, Chung JH, Kim KH, Eun HC, Cho KH — Biological and Pharmaceutical Bulletin, 2006 PubMed ↗
Minoxidil: mechanisms of action on hair growth
Messenger AG, Rundegren J — British Journal of Dermatology, 2004 PubMed ↗
Female pattern alopecia: current treatment concepts
Ramos PM, Miot HA — Anais Brasileiros de Dermatologia, 2015 PubMed ↗
Frequently Asked Questions
What is androgenetic alopecia?
Androgenetic alopecia (AGA) is a progressive, non-scarring condition in which genetically susceptible hair follicles respond to androgen hormones, principally DHT, by gradually miniaturising over successive growth cycles. It is the most common cause of hair loss in both men and women, following recognisable patterns that reflect regional differences in androgen receptor expression across the scalp.
Is AGA inherited from the mother's side?
Partially. The androgen receptor gene on the X chromosome is among the strongest genetic risk factors, and because men inherit their X from their mothers, maternal-line baldness is a stronger predictor than paternal-line. But AGA is polygenic, and genome-wide studies have identified many additional risk loci on autosomal chromosomes inherited from either parent. Looking only at the maternal family history gives an incomplete picture of risk.
Can androgenetic alopecia be reversed?
Partially, particularly when addressed early. DHT suppression via 5-AR inhibitors can halt progression and has been shown to produce measurable regrowth in users whose follicles retain sufficient function. Advanced miniaturisation with significant follicle atrophy is less responsive. There is no currently available treatment that reverses severe long-standing AGA without hair transplantation.
What is the difference between finasteride and dutasteride?
Finasteride inhibits only the type II isoform of 5-alpha reductase, while dutasteride inhibits both type I and type II. This produces more complete DHT suppression with dutasteride, and some comparative studies suggest greater efficacy for hair retention. The broader hormonal impact is correspondingly more pronounced. Both are prescription medications requiring clinical assessment before use.
Do copper peptides help with hair loss?
Research suggests copper peptides, particularly AHK-Cu (Copper Tripeptide-3), can upregulate VEGF in dermal papilla cells and support anagen-phase activity. They do not act on the androgen pathway and are not a substitute for DHT-targeted treatments in progressing AGA. Their role in a hair loss protocol is as a complementary topical active, addressing the vascular and growth-cycle dimensions of the scalp environment rather than the hormonal one.
How long does it take to see results from AGA treatment?
The minimum meaningful assessment period for most interventions is six months; twelve months is more reliable. Changes at the follicle level take multiple hair cycles to become visible as changes in density and coverage. For a detailed breakdown by treatment category and realistic outcome ranges, the article on how long before you see results covers this in full.
Why do the back and sides of the scalp keep their hair?
Occipital follicles, those at the back and sides of the scalp, express androgen receptors at lower levels than follicles in the temporal and vertex regions. This is an intrinsic property of those follicle populations, not a difference in the hormonal environment they are exposed to. It is also why hair transplants sourced from the back of the scalp retain their characteristics after relocation to the vertex: the follicle carries its resistance with it.
Is my hair loss AGA or something else?
AGA follows a patterned presentation: temporal recession and vertex thinning in men, diffuse crown thinning with a preserved frontal hairline in women. Sudden diffuse shedding is more consistent with telogen effluvium, which has a different cause and course. The two can coexist. The article on telogen effluvium vs androgenetic alopecia covers how to distinguish them, though a dermatological assessment remains the most reliable approach to diagnosis.
This article is provided for educational purposes. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition. For prescription treatments including finasteride or dutasteride, consult a qualified healthcare professional.
AmpleLab.